This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be acknowledged.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
The VA cares for an estimated 175,000 Veterans annually in their cancer treatment program. Radiation treatment for curative or definitive cancer therapy is an important and frequently used option. The Evidence Synthesis Program (ESP) is responding to a request from the Department of Veterans Affairs (VA) National Radiation Oncology Quality Task Force for an evidence review on the comparative effectiveness of hypofractionation versus conventional radiation therapy for adults with breast, prostate, lung, rectal, head and neck, bladder, pancreas, melanoma, or non-melanoma skin cancers.
Contents
- PREFACE
- ACKNOWLEDGMENTS
- ABBREVIATIONS TABLE
- EXECUTIVE SUMMARY
- INTRODUCTION
- METHODS
- RESULTS
- DISCUSSION
- REFERENCES
- APPENDIX A. SEARCH STRATEGIES
- APPENDIX B. EXCLUDED STUDIES
- APPENDIX C. PEER REVIEW DISPOSITION
- APPENDIX D. BREAST CANCER
- APPENDIX E. PROSTATE CANCER TABLES
- APPENDIX F. LUNG CANCER TABLES
- APPENDIX G. HEAD AND NECK CANCER TRIALS
- APPENDIX H. RECTAL CANCER TRIALS
Suggested citation:
Landsteiner A, Sowerby C, Ullman K, et al. Hypofractionation Radiation Therapy for Definitive Treatment of Selected Cancers: A Systematic Review. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project 09-009; 2023.
This report was prepared by the Evidence Synthesis Program Center located at the Minneapolis VA Health Care System, directed by Timothy J. Wilt, MD, MPH and Wei Duan-Porter, MD, PhD and funded by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development.
The findings and conclusions in this document are those of the author(s) who are responsible for its contents and do not necessarily represent the views of the Department of Veterans Affairs or the United States government. Therefore, no statement in this article should be construed as an official position of the Department of Veterans Affairs. No investigators have any affiliations or financial involvement (eg, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties) that conflict with material presented in the report.
- *
These are all lead authors who contributed equally to this report.
- NLM CatalogRelated NLM Catalog Entries
- Review Consensus Quality Measures and Dose Constraints for Breast Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel.[Pract Radiat Oncol. 2023]Review Consensus Quality Measures and Dose Constraints for Breast Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel.Puckett LL, Kodali D, Solanki AA, Park JH, Katsoulakis E, Kudner R, Kapoor R, Kujundzic K, Chapman CH, Hagan M, et al. Pract Radiat Oncol. 2023 May-Jun; 13(3):217-230. Epub 2022 Sep 15.
- Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Quality Measures Initiative.[Pract Radiat Oncol. 2022]Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Quality Measures Initiative.Park J, Puckett LL, Katsoulakis E, Venkatesulu BP, Kujundzic K, Solanki AA, Movsas B, Simone CB 2nd, Sandler H, Lawton CA, et al. Pract Radiat Oncol. 2022 Nov-Dec; 12(6):468-474. Epub 2022 Jun 8.
- Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel.[Pract Radiat Oncol. 2023]Consensus Quality Measures and Dose Constraints for Prostate Cancer From the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel.Solanki AA, Puckett LL, Kujundzic K, Katsoulakis E, Park J, Kapoor R, Hagan M, Kelly M, Palta J, Ballas LK, et al. Pract Radiat Oncol. 2023 Mar-Apr; 13(2):e149-e165. Epub 2022 Dec 9.
- Consensus Quality Measures and Dose Constraints for Head and Neck Cancer with an emphasis on Oropharyngeal and Laryngeal Cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel.[Pract Radiat Oncol. 2022]Consensus Quality Measures and Dose Constraints for Head and Neck Cancer with an emphasis on Oropharyngeal and Laryngeal Cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel.Katsoulakis E, Kudner R, Chapman C, Park J, Puckett L, Solanki A, Kapoor R, Hagan M, Kelly M, Palta J, et al. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):409-423. Epub 2022 Jun 4.
- Review Evidence Brief: Comparative Effectiveness of Appointment Recall Reminder Procedures for Follow-up Appointments[ 2015]Review Evidence Brief: Comparative Effectiveness of Appointment Recall Reminder Procedures for Follow-up AppointmentsPeterson K, McCleery E, Anderson J, Waldrip K, Helfand M. 2015 Jul
- Hypofractionation Radiation Therapy for Definitive Treatment of Selected Cancers...Hypofractionation Radiation Therapy for Definitive Treatment of Selected Cancers: A Systematic Review
Your browsing activity is empty.
Activity recording is turned off.
See more...